Tranexamic acid(TXA) is an antifibrinolytic agent to reduce blood loss in cardiac surgery. Previous seven RCTs comparing effects of TXA in pediatric cardiac surgery showed conflict results. The reason why they showed mixed results would be the imbalance of patients population with regard to presence of cyanosis. TXA would reduce blood loss in pediatric cardiac surgery with well balanced patients population.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
160
50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit in TXA group. same volume of normal saline was given in Placebo group.
the amount of blood loss (mediastinal and pericardial tube drainage) 24 hours after surgery
Time frame: 24 hours after surgery
blood loss 6 hours after surgery
Time frame: 6 hours after surgery
the amount of blood transfusion
Time frame: 24 hour after surgery
additional TXA administration
Time frame: 24 hours after surgery
chest closure time (protamine to skin closure)
Time frame: at the end of surgery
re-exploration of chest for excess bleeding
Time frame: within 24 hours after surgery
duration of mechanical ventilation
Time frame: at the time of extubation
length of stay in intensive care unit
Time frame: at the time of discharge from ICU
episode of thrombotic complication
Time frame: from drug administration to hospital discharge
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.